Literature DB >> 10574262

Hepatocyte growth factor and invasion-stimulatory activity are induced in pleural fluid by surgery in lung cancer patients.

A Uchiyama1, T Morisaki, K Beppu, M Kojima, Y Matsunari, A Nakatsuka, K Mizumoto, K Matsumoto, T Nakamura, M Tanaka.   

Abstract

Hepatocyte growth factor (HGF) is a stromal cell-derived cytokine that can stimulate matrix invasion by carcinoma cells. We analysed the concentrations of HGF and invasion-stimulatory activity in pleural fluid after lung surgery. The concentration of HGF in pleural fluids was measured by enzyme-linked immunosorbent assay in seven patients who underwent pulmonary resection for primary or metastatic lung cancer. The effect of the pleural fluid on cancer cell invasion across reconstituted basement membrane (Matrigel) was assessed with a Boyden chamber assay using a lung adenocarcinoma cell line, A549. HGF levels in the pleural fluid after lung surgery ranged from 6.0 to 23.0 ng ml(-1) (average: 10.2 +/- 4.3 ng ml(-1)). The matrix invasion of lung carcinoma cells in the presence of the pleural fluid was significantly higher than that in the presence of culture medium alone or sera from normal subjects (P < 0.01). The invasion-stimulatory activity of the pleural fluid was strongly inhibited by HGF-neutralizing antibody. Positive correlation was found between the HGF level and invasion-stimulatory activity in the pleural fluids and normal sera (P = 0.0073). This is the first report demonstrating that the lung surgery induces a considerable amount of HGF, which is closely correlated with the invasion-stimulatory activity of the pleural fluid.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10574262      PMCID: PMC2362901          DOI: 10.1038/sj.bjc.6690754

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  28 in total

1.  Assessment of the invasive potential of human gynecological tumor cell lines with the in vitro Boyden chamber assay: influences of the ability of cells to migrate through the filter membrane.

Authors:  A M Sieuwerts; J G Klijn; J A Foekens
Journal:  Clin Exp Metastasis       Date:  1997-01       Impact factor: 5.150

2.  Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer.

Authors:  J M Siegfried; L A Weissfeld; P Singh-Kaw; R J Weyant; J R Testa; R J Landreneau
Journal:  Cancer Res       Date:  1997-02-01       Impact factor: 12.701

3.  Plasma hepatocyte growth factor levels are increased in systemic inflammatory response syndrome.

Authors:  M Sakon; Y Kita; T Yoshida; K Umeshita; M Gotoh; T Kanai; T Kawasaki; J Kambayashi; M Monden
Journal:  Surg Today       Date:  1996       Impact factor: 2.549

4.  Significant elevation of serum human hepatocyte growth factor levels in patients with acute pancreatitis.

Authors:  T Ueda; Y Takeyama; A Toyokawa; S Kishida; M Yamamoto; Y Saitoh
Journal:  Pancreas       Date:  1996-01       Impact factor: 3.327

5.  Interleukin 4 inhibits hepatocyte growth factor-induced invasion and migration of colon carcinomas.

Authors:  A Uchiyama; R Essner; F Doi; T Nguyen; K P Ramming; T Nakamura; D L Morton; D S Hoon
Journal:  J Cell Biochem       Date:  1996-09-15       Impact factor: 4.429

6.  Induction of hepatocyte growth factor in fibroblasts by tumor-derived factors affects invasive growth of tumor cells: in vitro analysis of tumor-stromal interactions.

Authors:  T Nakamura; K Matsumoto; A Kiritoshi; Y Tano; T Nakamura
Journal:  Cancer Res       Date:  1997-08-01       Impact factor: 12.701

7.  Enhanced tumorigenicity and invasion-metastasis by hepatocyte growth factor/scatter factor-met signalling in human cells concomitant with induction of the urokinase proteolysis network.

Authors:  M Jeffers; S Rong; G F Vande Woude
Journal:  Mol Cell Biol       Date:  1996-03       Impact factor: 4.272

8.  Proliferative response of human and animal tumours to surgical wounding of normal tissues: onset, duration and inhibition.

Authors:  A E Bogden; J P Moreau; P A Eden
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

9.  Acquisition of invasive phenotype in gallbladder cancer cells via mutual interaction of stromal fibroblasts and cancer cells as mediated by hepatocyte growth factor.

Authors:  K Matsumoto; K Date; H Shimura; T Nakamura
Journal:  Jpn J Cancer Res       Date:  1996-07

10.  Detection of ras gene mutations in perioperative peripheral blood with pancreatic adenocarcinoma.

Authors:  S Nomoto; A Nakao; Y Kasai; A Harada; T Nonami; H Takagi
Journal:  Jpn J Cancer Res       Date:  1996-08
View more
  5 in total

Review 1.  Pleural mesothelial cells in pleural and lung diseases.

Authors:  Hitesh Batra; Veena B Antony
Journal:  J Thorac Dis       Date:  2015-06       Impact factor: 2.895

2.  Suppression of tumor recurrence and metastasis by a combination of the PHSCN sequence and the antiangiogenic compound tetrathiomolybdate in prostate carcinoma.

Authors:  Kenneth L van Golen; LiWei Bao; George J Brewer; Kenneth J Pienta; Jeffrey M Kamradt; Donna L Livant; Sofia D Merajver
Journal:  Neoplasia       Date:  2002 Sep-Oct       Impact factor: 5.715

3.  NK4, a four-kringle antagonist of HGF, inhibits spreading and invasion of human pancreatic cancer cells.

Authors:  N Maehara; K Matsumoto; K Kuba; K Mizumoto; M Tanaka; T Nakamura
Journal:  Br J Cancer       Date:  2001-03-23       Impact factor: 7.640

4.  A novel bispecific EGFR/Met antibody blocks tumor-promoting phenotypic effects induced by resistance to EGFR inhibition and has potent antitumor activity.

Authors:  R Castoldi; V Ecker; L Wiehle; M Majety; R Busl-Schuller; M Asmussen; A Nopora; U Jucknischke; F Osl; S Kobold; W Scheuer; M Venturi; C Klein; G Niederfellner; C Sustmann
Journal:  Oncogene       Date:  2013-07-01       Impact factor: 9.867

5.  Partial hepatectomy enhances the growth of CC531 rat colorectal cancer cells both in vitro and in vivo.

Authors:  Borja Herrero de la Parte; Mikel González-Arribas; Iñaki Diaz-Sanz; Teodoro Palomares; Ignacio García-Alonso
Journal:  Sci Rep       Date:  2021-03-08       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.